Introduction
The mitochondrial NADH :ubiquinone oxidoreductase (complex I) transfers electrons from NADH to ubiquinone via a sequence of redox reactions coupled to the vectorial translocation of protons across the inner mitochondrial membrane. It is the least-understood redox enzyme of the respiratory chain, due to its high degree of complexity. Despite the substantial progress made in the investigation of structure and function, important problems still have to be solved. For example, the number of quinone-binding sites is currently a matter of debate. In fact, there seems to be a growing consensus in the literature that two bound quinones could mechanistically explain the 4H+/2e-stoichiometry observed for the overall reaction [l] and could also account for the two semiquinone EPR signals [2] . So it becomes immediately clear that defining the number and specificity of quinone-binding sites would help to experimentally scrutinize the suggested models. In this respect, specific quinone-site inhibitors will be valuable tools.
Complex I has been recognized in applied agrochemical research as the molecular target site for new acaricides and insecticides from the pyrazole and the aminopyrimidine chemical classes [3, 4] . Consequently, agrochemical synthesis has significantly contributed to the impressive array of new inhibitor structures now available.
Based on enzyme-kinetic analysis, complex-I inhibitors were grouped into two or even three classes [5,6]. Class-I compounds, like piericidin and the acaricide fenpyroximate, blocked ubiquinone-2 reduction in a partially competitive manner. Rotenone, representing class 11, was found to be a non-competitive inhibitor [5]. This was taken as an indication that there were two inhibitor-interaction sites which would be related to the corresponding number of quinone-binding Abbreviations used: decylQ. n-decyl ubiquinone analogue; AE F I I 7233, 4-(cis-4-t-butylcyclohexylamino)-5-chlor-6-ethyl pyrimidine; 6,. maximum number of binding sites.
sites. The inhibition of the ubiquinone-dependent glucose dehydrogenase of Gluconobacter oxidans by class-I compounds was taken as a second distinctive criterion [5] .
We have studied the interaction of substituted aminopyrimidines (Figure 1 ) with complex I from housefly Musca domestica flight-muscle mitochondria. Inhibition of membrane-bound and solubilized complex I and other quinone-dependent dehydrogenases was determined to characterize our compounds in terms of efficiency and quinonesite specificity. Two tritiated inhibitors, the aminopyrimidine AE F119209 (defined in the legend to Figure 1 ) and dihydro-rotenone, were used in radioligand-binding studies with solubilized and partially purified housefly complex I.
Inhibition of complex I and other quinone-dependent dehydrogenases
NADH :ubiquinone oxidoreductase was measured in submitochondrial membranes prepared from M . domestica flight muscles with initial activity rates ranging from 30 to 40 nkat/mg of membrane protein at 50 pM n-decyl ubiquinone (decylQ) and 100 pM NADH. The aminopyrimidine compounds 4-( 2-decylamino)-5-methoxy-6-methoxymethyl pyrimidine (AE F110779) and 4-(cis-4-tbutylcyclohexylamino)-5-chlor-6-ethyl pyrimidine (AE F117233; Figure 1 ) blocked decylQdependent NADH oxidation with IC,, values of 2.0 and 0.4 nM, respectively. Inhibitor-insensitive NADH oxidation never exceeded 5 yo of the total activity. Complex-I inhibition by aminopyrimidines was found to be partially competitive with respect to the quinone substrate [7] .
With membrane-bound mitochondrial NADH :ubiquinone oxidoreductases from different biological sources, like rat heart, Neurospora crassa and the plant-pathogenic fungus Botrytis cinerea, AE F117233 was equally effective with IC,, values in the sub-nanomolar range. Testing bacterial electron-transport systems, the protontranslocating complex-I homologues (NDH I) from Paracoccus denitrificans and Escherichia coli were inhibited. The NDH-11-type NADH dehydrogenases from E . coli and Pseudomonas jlu- orescens were not affected by concentrations up to 10 pM. Interestingly, the aminopyrimidines inhibited 50 yo of the quinone-dependent glucose dehydrogenase of Acinetobacter calcoaceticus at lower micromolar concentrations. Double-reciprocal plots of activity versus decylQ concentration revealed a quinone-competitive inhibitor mechanism for this enzyme. Taken together, the results were consistent with a class I/type A inhibitor classification as quinone antagonists, according to Friedrich et al. [5] and Degli Esposti [6], respectively.
It is important to consider a general phenomenon of kinetic analyses with membrane-bound complex I coming from the physicochemical properties of the substrate quinone analogues and inhibitors. The hydrophobic or amphiphilic molecules tend to accumulate in the lipid phase. Therefore it can be expected that the actual free substratelinhibitor concentrations at the quinonebinding site(s) will be substantially higher than originally adjusted in the assay mix [8] . Kinetic calculations will always be ambiguous without taking into account the membrane volume and the particular partition coefficients.
The development of efficient purification protocols to prepare enzymatically active and inhibitor-sensitive mitochondria1 NADH :ubiquinone oxidoreductase opened up the possibilities for avoiding the problems caused by the hydrophobic membrane environment in both enzymatic and radioligand studies [9] .
Solubilization with dodecyl-maltoside and partial purification by gel filtration and QSepharose anion-exchange chromatography yielded an active and rotenone-sensitive housefly complex-I preparation with a specific activity of 4 W 5 nkat/mg of protein. The enzymatic activity plotted as a function of the decylQ concentration was best-fitted to the Hill equation
, with a Hill coefficient, h, of 1.7 (Figure 2) . Similar results were obtained with bovine heart complex I prepared under the same conditions. The data indicated heterogeneous or co-operative quinone-binding sites and corroborated an earlier report by Jewess showing a sigmoidal relationship between NADH oxidation and Q1 concentration (an ubiquinone analogue with one isoprenoid unit; Hill coefficient of 1.9) determined with blowfly (Lucilia caesar) submitochondrial membranes [lo] .
The aminopyrimidine inhibitor AE F117233, as well as rotenone (results not shown), revealed non-competitive behaviour in double-reciprocal plots of initial activity rates versus decylQ concentrations ( Figure 3) . By changing the 4-substituent of the cyclohexyl ring in AE F117233 systematically, a strong positive correlation ( r = 0.92, n = 13) was found between the PI,, (-log 1C5,) measured with soluble complex I and the capacity factors on reversed-phase HPLC, indicating that at least part of the enzymeinhibitor interaction was governed by hydrophobic properties of the inhibitors.
Radioligand binding to complex I
Radioligand-binding protocols have been successfully applied in neurochemistry to characterize the binding sites for low-molecular-mass ligands of neurotransmitter receptors and ion channels. Conclusions can be drawn on the number and pharmacological specificity of binding sites, as well as on possible allosteric interactions of compounds binding at different sites. Therefore it seemed obvious to employ these methods in the analysis of complex-I inhibitor site(s). Almost 30 years ago, labelling experiments with [14C]piericidin of either electron-transport particles or submitochondrial membranes were performed [ 1 11. In essence, the titration curves In all the binding analyses cited above, the formulation of meaningful binding kinetics was impossible due to large non-specific (hydrophobic) binding of radioligands to the lipid phase. We therefore attempted to establish a method using the solubilized, partially purified complex-I preparation described above. Additionally, saturation-binding assays were performed with [3H]AE F119209 in the presence or absence of a constant concentration of rotenone, piericidin or AE F117233. In each case, the apparent B,,, was not altered. T h e reverse experiments with labelled dihydro-rotenone and unlabelled rotenone, piericidin or AE F117233 gave essentially the same results. Despite their structural differences, the compounds displaced each other from the same or overlapping binding site(s).
Furthermore, the IC,, values of selected complex-I inhibitors were determined from competition binding experiments at a fixed radioligand concentration (near the dissociation constant) and variable inhibitor concentrations. T h e apparent inhibitor constants, K,, were calculated from the
where [L] is the free radioligand concentration and Kd the dissociation constant for the radioligand [14] . The following K, values were found with [3H]AE F119209: piericidin A, 5.7 n M ; rotenone, 12 n M ; fenpyroximate, 21 n M ; and rolliniastatin-1, 4.8 nM.
In summary, we have developed a radioligand-binding method with partially purified complex I from housefly mitochondria which allowed us (i) to experimentally determine the basic kinetic parameters excluding non-specific effects from the membrane environment, and (ii) to characterize inhibitors of different chemical classes in terms of affinity and binding-site specificity. T h e apparent K i values of selected aminopyrimidines and pyrazoles were found to be in the same range as the IC,, values measured in enzymeactivity assays using the soluble enzyme preparation. Our data favour a single binding domain with identical or at least overlapping interaction sites that accommodates a wide array of structurally diverse compounds.
T h e results are in fact difficult to reconcile with the earlier suggestion of independent inhibitor-binding sites for rotenone and piericidin. It is not possible, a priori, to exclude that during the purification process, although yielding an active and inhibitor-sensitive enzyme preparation, the complex was structurally modified so that we worked with a somewhat artificial system. On the other hand, the data were in excellent agreement with recently published results based on an independent method, the fluorescence-quench titration using bovine heart complex I in its natural membrane environment [ 131, showing essentially the same mutual displacement of rotenone and piericidin.
Conclusions and outlook
T h e considerable improvement of solubilization and purification methodology offer new opportunities for the investigation of quinone-binding sites in complex I. In radioligand-binding studies, representative class-I and class-I I inhibitors competitively displaced the dihydro-rotenone and aminopyrimidine ligands, questioning the suggested classification scheme. There seems to be only one inhibitor-binding domain. From our results, it is not possible to draw a decisive conclusion regarding the number of quinonebinding sites, since the substrate quinone analogues we tested showed weak if any displacement of the high-affinity radioligands. A plausible hypothesis to correlate quinone-and inhibitor-binding sites would be that two ubiquinones are bound to complex I at different sites but only one quinone is freely exchanging with the mobile quinone pool. At this site the quinone-site inhibitors might interfere with quinone binding and/or exchange with the pool quinone. T h e identification and characterization of new inhibitors might be helpful to is substantial evidence for two different sites of reaction with exogenous quinones [6, 7] , there is still contradictory evidence regarding the binding sites for the plethora of complex-I inhibitors that presumably act as quinone antagonists [1,2,8-lo] . Because some inhibitors such as myxothiazol and stigmatellin are common to complex I and other quinone-reacting systems [8, 11] , analogies can be drawn with the known structures and mechanisms of these systems, especially with complex I11 [4, 5] . These analogies can help in rationalizing mechanistic concepts and possibly also structure-function relationships [5] but, without new evidence, cannot solve a basic dilemma in complex-I research. Does the enzyme have a single pocket capable of accommodating a large variety of chemically different inhibitors [1,9,10], or multiple distinct sites for inhibitor binding and action [5, 8] ? T o further address this dilemma, we present
